The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biomarkers associated with outcomes from OPTIMIZE-1: CD40 agonist mitazalimab with mFOLFIRINOX in patients with untreated metastatic pancreatic cancer.
 
Philippe Cassier
Consulting or Advisory Role - Boehringer Ingelheim; Brenus Pharma; Bristol-Myers Squibb/Celgene; OSE Immunotherapeutics; Scenic Biotech; START
Research Funding - Abbvie (Inst); Adlai Nortye (Inst); Alligator Bioscience (Inst); Amgen (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Daiichi Sankyo/UCB Japan (Inst); Debiopharm Group (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Molecular Partners (Inst); Novartis (Inst); OSE Immunotherapeutics (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Roche/Genentech (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
(OPTIONAL) Uncompensated Relationships - ReACT Therapeutics
 
Jean-Luc Van Laethem
No Relationships to Disclose
 
Ivan Borbath
No Relationships to Disclose
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Alligator Bioscience; Amgen; Aptitude Health; Arcus Biosciences; AstraZeneca; Basilea; Baxter; BioLineRX; Boehringer Ingelheim; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Novocure; Paraxel; PEGASCY; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Taiho / Keylates; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Karen Geboes
Consulting or Advisory Role - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Ipsen (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Speakers' Bureau - BMS (Inst); Ipsen (Inst)
Expert Testimony - servier (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); MSD (Inst); servier (Inst)
 
Aurélien Lambert
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Ipsen; Janssen; Merck KGaA; Merck Serono; Novartis; Pierre Fabre; Servier/Pfizer
Travel, Accommodations, Expenses - Merck KGaA; Pfizer
 
Hans Prenen
Honoraria - Amgen; AstraZeneca; Merck
Consulting or Advisory Role - AstraZeneca; Biocartis
 
Emmanuel Mitry
Honoraria - AstraZeneca/Daiichi Sankyo; Bayer; Esteve; MSD; Pierre Fabre; SERVIER; Viatris
Travel, Accommodations, Expenses - MSD; Pierre Fabre
 
Jean-Frédéric Blanc
Honoraria - AstraZeneca; Bayer Schering Pharma; Eisai; INCYTE; IPSEN; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IPSEN; ROCHE; SERVIER; Taiho Pharmaceutical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca; IPSEN; Roche
 
Jaime Feliú
Consulting or Advisory Role - Amgen; AstraZeneca; Roche/Genentech; Viatris
Research Funding - Amgen; Amgen
Travel, Accommodations, Expenses - Amgen
 
Roberto Pazo Cid
Consulting or Advisory Role - Astellas Pharma; AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Eisai Europe; Ipsen; Roche; SERVIER
Speakers' Bureau - Astellas Pharma; AstraZeneca Spain; BMS GmbH & Co. KG; SERVIER
Travel, Accommodations, Expenses - Astellas Pharma; BMS GmbH & Co. KG; Lilly; Roche/Genentech; SERVIER
 
Inmaculada Gallego Jiménez
No Relationships to Disclose
 
Karin Enell Smith
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Alligator Bioscience
 
Karin Nordbladh
Employment - Alligator Biosence AB
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Listed as one of the inventors for combination treatment in development at Alligator Bioscience. Patent reference: WO2023247660A1
 
Yago Pico de Coaña
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Inventor on patents assigned to Alligator Bioscience
Travel, Accommodations, Expenses - Alligator Bioscience
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
David Gomez Jimenez
Employment - Alligator Bioscience
Stock and Other Ownership Interests - Pfizer
Research Funding - Alligator Bioscience; Asgard therapeutics
Patents, Royalties, Other Intellectual Property - Title: Combination therapy PCT application number: PCT/EP2023/066889 (Inst)
Travel, Accommodations, Expenses - Alligator Bioscience
 
Sumeet Ambarkhane
Employment - Alligator Bioscience; MorphoSys
Leadership - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience; MorphoSys
Patents, Royalties, Other Intellectual Property - Patent under review
Travel, Accommodations, Expenses - Alligator Bioscience; MorphoSys
 
Peter Ellmark
Employment - Alligator Bioscience
Leadership - Alligator Bioscience
Stock and Other Ownership Interests - Alligator Bioscience
Patents, Royalties, Other Intellectual Property - Inventor on patents assigned to Alligator Bioscience
 
Gregory Beatty
Stock and Other Ownership Interests - Johnson & Johnson; Pfizer
Consulting or Advisory Role - Alligator Bioscience; EMD Serono; Incyte; Legend Biotech; LianBio; Molecular Partners; Pancreatic Cancer Action Network
Research Funding - Alligator Bioscience; Bristol-Myers Squibb; Genmab; Gilead Sciences; HiberCell; Incyte
Patents, Royalties, Other Intellectual Property - Inventor of intellectual property related to mesothelin CAR T cells that is licensed by the University of Pennsylvania to Novartis.; Inventor of intellectual property related to mesothelin CAR T cells that is licensed by the University of Pennsylvania to Tmnuity.
 
OPTIMIZE-1 Investigators
No Relationships to Disclose